{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T12:35:36Z","timestamp":1780490136891,"version":"3.54.1"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T00:00:00Z","timestamp":1589846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>We conducted a questionnaire survey of oncology specialists to investigate the frequency of administration of different drugs for the management of chemotherapy-induced peripheral neuropathy in Japan in 2015. Our group published Clinical Guidelines for the Management of Chemotherapy-Induced Peripheral Neuropathy in 2017 (CIPN-GL2017). In these guidelines, we recommended duloxetine only. To verify the effect of the publication of the CIPN-GL2017, we conducted a questionnaire survey in 2019.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In 2015 and again in 2019, we investigated the use of vitamin B12, antiepileptic agents, duloxetine, antidepressants other than duloxetine, non-steroidal anti-inflammatory drugs, opioids and the Kampo compound (goshajinkigan) in a questionnaire employing a three-point scale wherein A implies routine or prophylactic administration, B implies occasional administration and C implies infrequent administration.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We sent the questionnaires via email to 971 diplomates of the Subspecialty Board of Japanese Society of Medical Oncology in 2015 and 1239 diplomates in 2019. The administration ratio (A\u00a0+\u00a0B) of duloxetine for numbness and pain was 46.8 and 31.7%, respectively, in 2015 and 68.9% (P\u00a0&amp;lt;\u00a00.01) and 73.1% (P\u00a0&amp;lt;\u00a00.01) in 2019. In response to the question regarding awareness of the CIPN-GL2017, 53.2% of respondents to the 2019 questionnaire were aware of the CIPN-GL2017. Among the respondents with an awareness of the CIPN-GL2017, the prescription rate of duloxetine (78.3%) for pain was significantly higher than that among respondents without any awareness (67.4%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>It is possible that the publication of CIPN-GL2017 influenced administration preferences of oncology specialists.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyaa056","type":"journal-article","created":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T11:10:00Z","timestamp":1589022600000},"page":"897-902","source":"Crossref","is-referenced-by-count":15,"title":["Effects of the publication of Clinical Guidelines for the Management of Chemotherapy-Induced Peripheral Neuropathy on the Administration Preferences of Oncology Specialists: Japanese Association of Supportive Care in Cancer"],"prefix":"10.1093","volume":"50","author":[{"given":"Yasuo","family":"Hirayama","sequence":"first","affiliation":[{"name":"Department of Hematology Oncology, Higashi Sapporo Hospital, Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichiro","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Fukuoka University, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Mori","sequence":"additional","affiliation":[{"name":"Palliative Care Team, Seirei Mikatahara Hospital, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Tamura","sequence":"additional","affiliation":[{"name":"General Medical Research Center, Faculty of Medicine, Fukuoka University, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,5,19]]},"reference":[{"key":"2020080408004080300_ref1","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ejca.2009.12.008","article-title":"Chemotherapy-induced peripheral neurotoxicity assessment: a critical revision of the currently available tools","volume":"46","author":"Cavaletti","year":"2010","journal-title":"Eur J Cancer"},{"key":"2020080408004080300_ref2","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/annonc\/mds329","article-title":"The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings","volume":"24","author":"Cavaletti","year":"2013","journal-title":"Ann Oncol"},{"key":"2020080408004080300_ref3","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","article-title":"Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis","volume":"155","author":"Seretny","year":"2014","journal-title":"Pain"},{"key":"2020080408004080300_ref4","doi-asserted-by":"crossref","first-page":"e000053","DOI":"10.1136\/esmoopen-2016-000053","article-title":"Survey of the management of chemotherapy-induced peripheral neuropathy in Japan: Japanese Society of Medical Oncology","volume":"13","author":"Hirayama","year":"2016","journal-title":"ESMO Open"},{"key":"2020080408004080300_ref5","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2013.54.0914","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline","volume":"32","author":"Hershman","year":"2014","journal-title":"J Clin Oncol"},{"key":"2020080408004080300_ref6","volume-title":"Clinical Guide of Management for Chemotherapy-induced Peripheral Neuropathy 2017","author":"Japanese Association of Supportive Care in Cancer"},{"key":"2020080408004080300_ref7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/00004850-199705000-00003","article-title":"An open-label study of duloxetine hydrochloride, a mixed serotonin and noradrenaline reuptake inhibitor, in patients with DSM-III-R major depressive disorder. Lilly Duloxetine Depression Study Group","volume":"12","author":"Berk","year":"1997","journal-title":"Int Clin Psychopharmacol"},{"key":"2020080408004080300_ref8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.pain.2005.03.029","article-title":"Duloxetine vs. placebo in patients with painful diabetic neuropathy","volume":"116","author":"Goldstein","year":"2005","journal-title":"Pain."},{"key":"2020080408004080300_ref9","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2013.2813","article-title":"Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial","volume":"309","author":"Smith","year":"2013","journal-title":"JAMA"},{"key":"2020080408004080300_ref10","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1007\/s10147-015-0810-y","article-title":"Effect of duloxetine in Japanese patients with chemotherapy-induced peripheral neuropathy: a pilot randomized trial","volume":"20","author":"Hirayama","year":"2015","journal-title":"Int J Clin Oncol"},{"key":"2020080408004080300_ref11","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1002\/cncr.23008","article-title":"Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3)","volume":"110","author":"Rao","year":"2007","journal-title":"Cancer"},{"key":"2020080408004080300_ref12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jpainsymman.2007.02.043","article-title":"Amitriptyline in the treatment of chemotherapy-induced neuropathic symptom","volume":"35","author":"Kautio","year":"2008","journal-title":"J Pain Symptom Manage"},{"key":"2020080408004080300_ref13","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.pain.2009.03.013","article-title":"Non-steroidal anti-inflammatory drugs for neuropathic pain: how do we explain continued widespread use?","volume":"143","author":"Vo","year":"2009","journal-title":"Pain"},{"key":"2020080408004080300_ref14","author":"NCCN","year":"2016"},{"key":"2020080408004080300_ref15","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1007\/s00520-014-2132-4","article-title":"Efficacy and tolerability of controlled-release oxycodone for oxaliplatin-induced peripheral neuropathy and the extension of FOLFOX therapy in advanced colorectal cancer patients","volume":"22","author":"Nagashima","year":"2014","journal-title":"Support Care Cancer"},{"key":"2020080408004080300_ref16","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1007\/s00520-012-1511-y","article-title":"Controlled-release oxycodone for the treatment of bortezomib-induced neuropathic pain in patients with multiple myeloma","volume":"20","author":"Cartoni","year":"2012","journal-title":"Support Care Cancer"},{"key":"2020080408004080300_ref17","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3892\/etm.2011.375","article-title":"Objective evaluation of the alleviating effects of Goshajinkigan on peripheral neuropathy induced by paclitaxel\/carboplatin therapy: a multicenter collaborative study","volume":"3","author":"Kaku","year":"2012","journal-title":"Exp Ther Med"},{"key":"2020080408004080300_ref18","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s10147-015-0784-9","article-title":"Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study","volume":"20","author":"Oki","year":"2015","journal-title":"Int J Clin Oncol"},{"key":"2020080408004080300_ref19","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jpain.2004.12.007","article-title":"Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized controlled trial","volume":"6","author":"Richter","year":"2005","journal-title":"J Pain."},{"key":"2020080408004080300_ref20","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.pain.2004.01.001","article-title":"Pregabalin reduces pain and neuralgia; results of randomized placebo-controlled clinical trial","volume":"109","author":"Sabatowski","year":"2004","journal-title":"Pain"},{"key":"2020080408004080300_ref21","doi-asserted-by":"crossref","first-page":"52","DOI":"10.4103\/jrms.JRMS_1068_17","article-title":"The effect of pregabalin and duloxetine treatment on quality of life of breast cancer patients with taxane-induced sensory neuropathy: a randomized clinical trial","volume":"23","author":"Avan","year":"2018","journal-title":"Res Med Sci"},{"key":"2020080408004080300_ref22","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/jnci\/djx178","article-title":"Effects of Cryotherapy on objective and subjective symptoms of paclitaxel-induced neuropathy: prospective self-controlled trial","volume":"110","author":"Hanai","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"2020080408004080300_ref23","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.breast.2019.06.008","article-title":"Effectiveness and safety of surgical glove compression therapy as a prophylactic method against nanoparticle albumin-bound-paclitaxel-induced peripheral neuropathy","volume":"47","author":"Tsuyuki","year":"2019","journal-title":"The Breast"},{"key":"2020080408004080300_ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-019-05063-x","article-title":"Chemotherapy-induced peripheral neuropathy (CIPN) and its treatment: an NIH Collaboratory study of claims data","author":"Gewandter","year":"2019","journal-title":"Support Care Cancer"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/50\/8\/897\/33563527\/hyaa056.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/50\/8\/897\/33563527\/hyaa056.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T12:02:42Z","timestamp":1596542562000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/50\/8\/897\/5839902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,19]]},"references-count":24,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,5,19]]},"published-print":{"date-parts":[[2020,8,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyaa056","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,8]]},"published":{"date-parts":[[2020,5,19]]}}}